These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34298712)

  • 41. Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia.
    Yang X; Ma L; Zhang X; Huang L; Wei J
    Exp Hematol Oncol; 2022 Mar; 11(1):11. PubMed ID: 35236415
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia.
    Saxena K; Herbrich SM; Pemmaraju N; Kadia TM; DiNardo CD; Borthakur G; Pierce SA; Jabbour E; Wang SA; Bueso-Ramos C; Loghavi S; Tang G; Cheung CM; Alexander L; Kornblau S; Andreeff M; Garcia-Manero G; Ravandi F; Konopleva MY; Daver N
    Cancer; 2021 Oct; 127(20):3761-3771. PubMed ID: 34171128
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The palmitoyltransferase ZDHHC21 regulates oxidative phosphorylation to induce differentiation block and stemness in AML.
    Shao X; Xu A; Du W; Xu T; Huang Y; Xia Z; Wang W; Cai M; Zhang X; Zhang J; Cao J; Xu X; Yang B; He Q; Ying M
    Blood; 2023 Jul; 142(4):365-381. PubMed ID: 37216691
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis.
    Liu N; Wang C; Wang L; Gao L; Cheng H; Tang G; Hu X; Wang J
    Int J Mol Med; 2016 Jun; 37(6):1686-96. PubMed ID: 27082972
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diphenyleneiodonium Triggers Cell Death of Acute Myeloid Leukemia Cells by Blocking the Mitochondrial Respiratory Chain, and Synergizes with Cytarabine.
    Dakik H; El Dor M; Bourgeais J; Kouzi F; Herault O; Gouilleux F; Zibara K; Mazurier F
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626090
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells.
    Larrue C; Guiraud N; Mouchel PL; Dubois M; Farge T; Gotanègre M; Bosc C; Saland E; Nicolau-Travers ML; Sabatier M; Serhan N; Sahal A; Boet E; Mouche S; Heydt Q; Aroua N; Stuani L; Kaoma T; Angenendt L; Mikesch JH; Schliemann C; Vergez F; Tamburini J; Récher C; Sarry JE
    Nat Commun; 2021 Jan; 12(1):422. PubMed ID: 33462236
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mitocurcumin utilizes oxidative stress to upregulate JNK/p38 signaling and overcomes Cytarabine resistance in acute myeloid leukemia.
    Gaur T; Ali A; Sharma D; Gupta SK; Gota V; Bagal B; Platzbeckar U; Mishra R; Dutt A; Khattry N; Mills K; Hassan MI; Sandur S; Hasan SK
    Cell Signal; 2024 Feb; 114():111004. PubMed ID: 38048856
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting Mitochondrial Oxidative Phosphorylation Eradicates Acute Myeloid Leukemic Stem Cells.
    Peng M; Huang Y; Zhang L; Zhao X; Hou Y
    Front Oncol; 2022; 12():899502. PubMed ID: 35574326
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines.
    Illangeswaran RSS; Jebanesan DZP; Sivakumar KK; Vidhyadharan RT; Rajamani BM; Janet NB; David E; Velayudhan SR; Mathews V; Balasubramanian P
    Leuk Res; 2023 May; 128():107054. PubMed ID: 36906941
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Galectin-9 has non-apoptotic cytotoxic activity toward acute myeloid leukemia independent of cytarabine resistance.
    Choukrani G; Visser N; Ustyanovska Avtenyuk N; Olthuis M; Marsman G; Ammatuna E; Lourens HJ; Niki T; Huls G; Bremer E; Wiersma VR
    Cell Death Discov; 2023 Jul; 9(1):228. PubMed ID: 37407572
    [TBL] [Abstract][Full Text] [Related]  

  • 51. n-3 Polyunsaturated fatty acids induce acute myeloid leukemia cell death associated with mitochondrial glycolytic switch and Nrf2 pathway activation.
    Picou F; Debeissat C; Bourgeais J; Gallay N; Ferrié E; Foucault A; Ravalet N; Maciejewski A; Vallet N; Ducrocq E; Haddaoui L; Domenech J; Hérault O; Gyan E
    Pharmacol Res; 2018 Oct; 136():45-55. PubMed ID: 30142422
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interleukin-6 Facilitates Acute Myeloid Leukemia Chemoresistance via Mitofusin 1-Mediated Mitochondrial Fusion.
    Hou D; Zheng X; Cai D; You R; Liu J; Wang X; Liao X; Tan M; Lin L; Wang J; Zhang S; Huang H
    Mol Cancer Res; 2023 Dec; 21(12):1366-1378. PubMed ID: 37698549
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of Combinatory In Vitro Treatment with Immune Checkpoint Inhibitors and Cytarabine on the Anti-Cancer Immune Microenvironment in De Novo AML Patients.
    Bołkun Ł; Starosz A; Krętowska-Grunwald A; Wasiluk T; Walewska A; Wierzbowska A; Moniuszko M; Grubczak K
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275902
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metformin sensitizes AML cells to chemotherapy through blocking mitochondrial transfer from stromal cells to AML cells.
    You R; Wang B; Chen P; Zheng X; Hou D; Wang X; Zhang B; Chen L; Li D; Lin X; Huang H
    Cancer Lett; 2022 Apr; 532():215582. PubMed ID: 35122876
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cells.
    Ogbomo H; Michaelis M; Klassert D; Doerr HW; Cinatl J
    Neoplasia; 2008 Dec; 10(12):1402-10. PubMed ID: 19048119
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model.
    Zhang L; Gajewski TF; Kline J
    Blood; 2009 Aug; 114(8):1545-52. PubMed ID: 19417208
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimal AraC-Cytotoxicity to AML Cells Requires ERK5 Activity.
    Zheng R; Studzinski GP
    J Cell Biochem; 2017 Jun; 118(6):1583-1589. PubMed ID: 27922189
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia.
    Caldwell JT; Edwards H; Buck SA; Ge Y; Taub JW
    Pediatr Blood Cancer; 2014 Oct; 61(10):1767-73. PubMed ID: 24962331
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia.
    Laverdière I; Boileau M; Neumann AL; Frison H; Mitchell A; Ng SWK; Wang JCY; Minden MD; Eppert K
    Blood Cancer J; 2018 Jun; 8(6):52. PubMed ID: 29921955
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PD-L1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3K-AKT signaling pathway.
    Wang F; Yang L; Xiao M; Zhang Z; Shen J; Anuchapreeda S; Tima S; Chiampanichayakul S; Xiao Z
    Sci Rep; 2022 Jul; 12(1):11444. PubMed ID: 35794161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.